CoChat
Sign Up
Cited by 62Gut microbiota and healthCancer Research and TreatmentsCancer Immunotherapy and Biomarkers

Intratumoral microbiome: implications for immune modulation and innovative therapeutic strategies in cancer

Open access
Wang, Na, Wu, Si, Huang, Lanxiang, Hu, Yue, He, Xin, He, Jourong, Hu, Ben, Xu, Yaqi +4 more·2025·Journal of Biomedical Science
DOI 10.1186/s12929-025-01117-xPMC PMC11837407
Open this paper in CoChat — free accountOpen PDF

Abstract

Recent advancements have revealed the presence of a microbiome within tumor tissues, underscoring the crucial role of the tumor microbiome in the tumor ecosystem. This review delves into the characteristics of the intratumoral microbiome, underscoring its dual role in modulating immune responses and its potential to both suppress and promote tumor growth. We examine state-of-the-art techniques for detecting and analyzing intratumoral bacteria, with a particular focus on their interactions with the immune system and the resulting implications for cancer prognosis and treatment. By elucidating the intricate crosstalk between the intratumoral microbiome and the host immune system, we aim to uncover novel therapeutic strategies that enhance the efficacy of cancer treatments. Additionally, this review addresses the existing challenges and future prospects within this burgeoning field, advocating for the integration of microbiome research into comprehensive cancer therapy frameworks. Graphical Abstract

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12929-025-01117-x

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Bacteria within the tumor microenvironment play complex roles in tumor initiation, progression, and treatment response.

    “Increasing evidence indicates that bacteria within the TME play complex roles in tumor initiation, progression, and treatment response [36,37]”

    From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [36]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 174

  1. [2]Thomas S, Izard J, Walsh E, Batich K, Chongsathidkiet P, Clarke G, et al. The host microbiome regulates and maintains human health: a primer and perspective for non-microbiologists. Cancer Res. 2017;77(8):1783–812. 28292977 PMC5392374 · DOI
  2. [3]Gilbert JA, Blaser MJ, Caporaso JG, Jansson JK, Lynch SV, Knight R. Current understanding of the human microbiome. Nat Med. 2018;24(4):392–400. 29634682 PMC7043356 · DOI · Paper page
  3. [4]Li W, Chen QW, Fan JX, Han ZY, Song WF, Zeng X, et al. Bacterial biohybrids for invasion of tumor cells promote antigen cross-presentation through gap junction. Adv Mater. 2024;36(25): e2402532. 38563503 · DOI
  4. [5]Fu Y, Li J, Cai W, Huang Y, Liu X, Ma Z, et al. The emerging tumor microbe microenvironment: from delineation to multidisciplinary approach-based interventions. Acta Pharm Sin B. 2024;14(4):1560–91. 38572104 PMC10985043 · DOI · Paper page
  5. [6]Reboldi A, Cyster JG. Peyer’s patches: organizing B-cell responses at the intestinal frontier. Immunol Rev. 2016;271(1):230–45. 27088918 PMC4835804 · DOI
  6. [7]Shale M, Schiering C, Powrie F. CD4(+) T-cell subsets in intestinal inflammation. Immunol Rev. 2013;252(1):164–82. 23405904 PMC3736165 · DOI
  7. [8]Dai JH, Tan XR, Qiao H, Liu N. Emerging clinical relevance of microbiome in cancer: promising biomarkers and therapeutic targets. Protein Cell. 2024;15(4):239–60. 37946397 PMC10984626 · DOI
  8. [9]Gu J, Wang H, Zhang M, Xiong Y, Yang L, Ren B, et al. Application of fluorescence in situ hybridization (FISH) in oral microbial detection. Pathogens. 2022;11(12):1450. 36558784 PMC9788346 · DOI
  9. [10]Xie Y, Xie F, Zhou X, Zhang L, Yang B, Huang J, et al. Microbiota in tumors: from understanding to application. Adv Sci. 2022;9(21): e2200470. PMC9313476 35603968 · DOI
  10. [11]Chai X, Wang J, Li H, Gao C, Li S, Wei C, et al. Intratumor microbiome features reveal antitumor potentials of intrahepatic cholangiocarcinoma. Gut Microbes. 2023;15(1):2156255. 36563106 PMC9794006 · DOI · Paper page
  11. [12]Zwirglmaier K. Fluorescence in situ hybridisation (FISH)—the next generation. FEMS Microbiol Lett. 2005;246(2):151–8. 15899400 · DOI
  12. [13]Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn. 2012;14(1):22–9. 22166544 PMC3338343 · DOI
  13. [14]Galeano Niño JL, Wu H, LaCourse KD, Kempchinsky AG, Baryiames A, Barber B, et al. Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer. Nature. 2022;611(7937):810–7. 36385528 PMC9684076 · DOI · Paper page
  14. [15]Wu H, Leng X, Liu Q, Mao T, Jiang T, Liu Y, et al. Intratumoral microbiota composition regulates chemoimmunotherapy response in esophageal squamous cell carcinoma. Cancer Res. 2023;83(18):3131–44. 37433041 · DOI
  15. [16]Feng Z, Hu Y, Wang X, Li Y, Yu Y, He J, et al. In situ imaging for tumor microbiome interactions via imaging mass cytometry on single-cell level. Cytom Part A. 2022;101(8):617–29. 35301803 · DOI
  16. [17]Kalaora S, Nagler A, Nejman D, Alon M, Barbolin C, Barnea E, et al. Identification of bacteria-derived HLA-bound peptides in melanoma. Nature. 2021;592(7852):138–43. 33731925 PMC9717498 · DOI · Paper page
  17. [18]Weiner A, Enninga J. The pathogen-host interface in three dimensions: correlative FIB/SEM applications. Trends Microbiol. 2019;27(5):426–39. 30600140 · DOI
  18. [19]Susaki Etsuo A, Ueda HR. Whole-body and whole-organ clearing and imaging techniques with single-cell resolution: toward organism-level systems biology in mammals. Cell Chem Biol. 2016;23(1):137–57. 26933741 · DOI
  19. [20]Lee K, Lai HM, Soerensen MH, Hui ES, Ma VW, Cho WC, et al. Optimised tissue clearing minimises distortion and destruction during tissue delipidation. Neuropathol Appl Neurobiol. 2021;47(3):441–53. 33107057 PMC8048831 · DOI
  20. [21]DePas WH, Starwalt-Lee R, Van Sambeek L, Ravindra Kumar S, Gradinaru V, Newman DK. Exposing the three-dimensional biogeography and metabolic states of pathogens in cystic fibrosis sputum via hydrogel embedding, clearing, and rRNA labeling. MBio. 2016;7(5): e00796. 27677788 PMC5040109 · DOI
  21. [22]Wang W, Zhang N, Du Y, Gao J, Li M, Lin L, et al. Three-dimensional quantitative imaging of native microbiota distribution in the gut. Angew Chem Int Ed. 2021;60(6):3055–61. 33084179 · DOI
  22. [23]Zhao J, He D, Lai HM, Xu Y, Luo Y, Li T, et al. Comprehensive histological imaging of native microbiota in human glioma. J Biophotonics. 2022;15(4): e202100351. 34936211 · DOI
  23. [24]Liu Z, Parida S, Prasad R, Pandey R, Sharma D, Barman I. Vibrational spectroscopy for decoding cancer microbiota interactions: current evidence and future perspective. Semin Cancer Biol. 2022;86:743–52. 34273519 · DOI
  24. [25]Hong J-K, Kim SB, Lyou ES, Lee TK. Microbial phenomics linking the phenotype to function: the potential of Raman spectroscopy. J Microbiol. 2021;59(3):249–58. 33496936 · DOI
  25. [26]Große C, Bergner N, Dellith J, Heller R, Bauer M, Mellmann A, et al. Label-free imaging and spectroscopic analysis of intracellular bacterial infections. Anal Chem. 2015;87(4):2137–42. 25582952 · DOI
  26. [27]Silge A, Abdou E, Schneider K, Meisel S, Bocklitz T, Lu-Walther H-W, et al. Shedding light on host niches: label-free in situ detection of Mycobacterium gordonae via carotenoids in macrophages by Raman microspectroscopy. Cell Microbiol. 2015;17(6):832–42. 25488726 · DOI
  27. [28]Li M, Xu J, Romero-Gonzalez M, Banwart SA, Huang WE. Single cell Raman spectroscopy for cell sorting and imaging. Curr Opin Biotechnol. 2012;23(1):56–63. 22138495 · DOI
  28. [29]Liu M, Zhu P, Zhang L, Gong Y, Wang C, Sun L, et al. Single-cell identification, drug susceptibility test, and whole-genome sequencing of Helicobacter pylori directly from gastric biopsy by clinical antimicrobial susceptibility test Ramanometry. Clin Chem. 2022;68(8):1064–74. 35714147 · DOI
  29. [30]Xue C, Chu Q, Zheng Q, Yuan X, Su Y, Bao Z, et al. Current understanding of the intratumoral microbiome in various tumors. Cell Rep Med. 2023;4(1):100884. 36652905 PMC9873978 · DOI
  30. [31]Zhang N, Kandalai S, Zhou X, Hossain F, Zheng Q. Applying multi-omics toward tumor microbiome research. iMeta. 2023;2(1): e73. 38868335 PMC10989946 · DOI
  31. [32]Schriefer AE, Cliften PF, Hibberd MC, Sawyer C, Brown-Kennerly V, Burcea L, et al. A multi-amplicon 16S rRNA sequencing and analysis method for improved taxonomic profiling of bacterial communities. J Microbiol Methods. 2018;154:6–13. 30273610 PMC6375304 · DOI
  32. [33]Boesch M, Horvath L, Baty F, Pircher A, Wolf D, Spahn S, et al. Compartmentalization of the host microbiome: how tumor microbiota shapes checkpoint immunotherapy outcome and offers therapeutic prospects. J Immunother Cancer. 2022;10(11): e005401. 36343977 PMC9644363 · DOI
  33. [34]Guo W, Zhang Y, Guo S, Mei Z, Liao H, Dong H, et al. Tumor microbiome contributes to an aggressive phenotype in the basal-like subtype of pancreatic cancer. Commun Biol. 2021;4(1):1019. 34465850 PMC8408135 · DOI
  34. [35]Cheng WY, Liu WX, Ding Y, Wang G, Shi Y, Chu ESH, et al. High sensitivity of shotgun metagenomic sequencing in colon tissue biopsy by host DNA depletion. Genom Proteom Bioinform. 2023;21(6):1195–205. PMC11082407 36174929 · DOI
  35. [36]Sun Z, Huang S, Zhu P, Tzehau L, Zhao H, Lv J, et al. Species-resolved sequencing of low-biomass or degraded microbiomes using 2bRAD-M. Genome Biol. 2022;23(1):36. 35078506 PMC8789378 · DOI
  36. [37]Wang X, Zheng Y, Chen X, Peng C, Zhou S, Shen S, et al. 2bRAD-M reveals the difference in microbial distribution between cancerous and benign ovarian tissues. Front Microbiol. 2023;14:1231354. 37692387 PMC10484612 · DOI
  37. [38]Goolam Mahomed T, Peters R, Pretorius G, Goolam Mahomed A, Ueckermann V, Kock MM, et al. Comparison of targeted metagenomics and IS-Pro methods for analysing the lung microbiome. BMC Microbiol. 2021;21(1):228. 34407769 PMC8371770 · DOI
  38. [39]Picardo SL, Coburn B, Hansen AR. The microbiome and cancer for clinicians. Crit Rev Oncol Hematol. 2019;141:1–12. 31202124 · DOI
  39. [41]Xu Z, Wang Y, Sheng K, Rosenthal R, Liu N, Hua X, et al. Droplet-based high-throughput single microbe RNA sequencing by smRandom-seq. Nat Commun. 2023;14(1):5130. 37612289 PMC10447461 · DOI
  40. [42]Blattman SB, Jiang W, Oikonomou P, Tavazoie S. Prokaryotic single-cell RNA sequencing by in situ combinatorial indexing. Nat Microbiol. 2020;5(10):1192–201. 32451472 PMC8330242 · DOI
  41. [43]Kuchina A, Brettner LM, Paleologu L, Roco CM, Rosenberg AB, Carignano A, et al. Microbial single-cell RNA sequencing by split-pool barcoding. Science. 2021;371(6531): eaba5257. 33335020 PMC8269303 · DOI · Paper page
  42. [44]Ma P, Amemiya HM, He LL, Gandhi SJ, Nicol R, Bhattacharyya RP, et al. Bacterial droplet-based single-cell RNA-seq reveals antibiotic-associated heterogeneous cellular states. Cell. 2023;186(4):877-91.e14. 36708705 PMC10014032 · DOI · Paper page
  43. [45]Avital G, Avraham R, Fan A, Hashimshony T, Hung DT, Yanai I. scDual-Seq: mapping the gene regulatory program of Salmonella infection by host and pathogen single-cell RNA-sequencing. Genome Biol. 2017;18(1):200. 29073931 PMC5658913 · DOI
  44. [47]Wong-Rolle A, Dong Q, Zhu Y, Divakar P, Hor JL, Kedei N, et al. Spatial meta-transcriptomics reveal associations of intratumor bacteria burden with lung cancer cells showing a distinct oncogenic signature. J Immunother Cancer. 2022;10(7): e004698. 35793869 PMC9260850 · DOI
  45. [48]Lagier J-C, Dubourg G, Million M, Cadoret F, Bilen M, Fenollar F, et al. Culturing the human microbiota and culturomics. Nat Rev Microbiol. 2018;16(9):540–50. 29937540 · DOI
  46. [49]Matar G, Bilen M. Culturomics, a potential approach paving the way toward bacteriotherapy. Curr Opin Microbiol. 2022;69:102194. 35994842 · DOI
  47. [50]Diakite A, Dubourg G, Dione N, Afouda P, Bellali S, Ngom II, et al. Optimization and standardization of the culturomics technique for human microbiome exploration. Sci Rep. 2020;10(1):9674. 32541790 PMC7295790 · DOI
  48. [51]Sun Y, Liu Y, Li J, Tan Y, An T, Zhuo M, et al. Characterization of lung and oral microbiomes in lung cancer patients using culturomics and 16S rRNA gene sequencing. Microbiol Spectr. 2023;11(3): e0031423. 37092999 PMC10269771 · DOI
  49. [52]Guzman-Rodriguez M, McDonald JAK, Hyde R, Allen-Vercoe E, Claud EC, Sheth PM, et al. Using bioreactors to study the effects of drugs on the human microbiota. Methods. 2018;149:31–41. 30102990 · DOI
  50. [53]Villa MM, Bloom RJ, Silverman JD, Durand HK, Jiang S, Wu A, et al. Interindividual variation in dietary carbohydrate metabolism by gut bacteria revealed with droplet microfluidic culture. mSystems. 2020;5(3):10. PMC7329328 32606031 · DOI
  51. [54]Mahajan G, Doherty E, To T, Sutherland A, Grant J, Junaid A, et al. Vaginal microbiome-host interactions modeled in a human vagina-on-a-chip. Microbiome. 2022;10(1):201. 36434666 PMC9701078 · DOI
  52. [55]Cross KL, Campbell JH, Balachandran M, Campbell AG, Cooper CJ, Griffen A, et al. Targeted isolation and cultivation of uncultivated bacteria by reverse genomics. Nat Biotechnol. 2019;37(11):1314–21. 31570900 PMC6858544 · DOI
  53. [57]Van der Merwe M, Van Niekerk G, Botha A, Engelbrecht A-M. The onco-immunological implications of Fusobacterium nucleatum in breast cancer. Immunol Lett. 2021;232:60–6. 33647328 · DOI
  54. [58]Jain T, Sharma P, Are AC, Vickers SM, Dudeja V. New insights into the cancer-microbiome-immune axis: decrypting a decade of discoveries. Front Immunol. 2021;12:622064. 33708214 PMC7940198 · DOI
  55. [59]Mager DL. Bacteria and cancer: cause, coincidence or cure? A review. J Transl Med. 2006;4:14. 16566840 PMC1479838 · DOI
  56. [60]Chang AH, Parsonnet J. Role of bacteria in oncogenesis. Clin Microbiol Rev. 2010;23(4):837–57. 20930075 PMC2952975 · DOI
  57. [61]Mima K, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K, et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol. 2015;1(5):653–61. 26181352 PMC4537376 · DOI · Paper page
  58. [62]Borowsky J, Haruki K, Lau MC, Dias Costa A, Väyrynen JP, Ugai T, et al. Association of Fusobacterium nucleatum with specific T-cell subsets in the colorectal carcinoma microenvironment. Clin Cancer Res. 2021;27(10):2816–26. 33632927 PMC8127352 · DOI
  59. [63]Ma J, Gnanasekar A, Lee A, Li WT, Haas M, Wang-Rodriguez J, et al. Influence of intratumor microbiome on clinical outcome and immune processes in prostate cancer. Cancers. 2020;12(9):2524. 32899474 PMC7564876 · DOI
  60. [64]Gur C, Ibrahim Y, Isaacson B, Yamin R, Abed J, Gamliel M, et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. 2015;42(2):344–55. 25680274 PMC4361732 · DOI · Paper page
  61. [65]Gur C, Maalouf N, Shhadeh A, Berhani O, Singer BB, Bachrach G, et al. Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1. Oncoimmunology. 2019;8(6): e1581531. 31069151 PMC6492956 · DOI
  62. [66]Park HE, Kim JH, Cho NY, Lee HS, Kang GH. Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma. Virchows Arch. 2017;471(3):329–36. 28597080 · DOI
  63. [67]Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14(2):207–15. 23954159 PMC3772512 · DOI · Paper page
  64. [68]Chen T, Li Q, Wu J, Wu Y, Peng W, Li H, et al. Fusobacterium nucleatum promotes M2 polarization of macrophages in the microenvironment of colorectal tumours via a TLR4-dependent mechanism. Cancer Immunol Immunother. 2018;67(10):1635–46. 30121899 PMC11028377 · DOI
  65. [69]Hu L, Liu Y, Kong X, Wu R, Peng Q, Zhang Y, et al. Fusobacterium nucleatum facilitates M2 macrophage polarization and colorectal carcinoma progression by activating TLR4/NF-κB/S100A9 cascade. Front Immunol. 2021;12:658681. 34093546 PMC8176789 · DOI
  66. [70]Udayasuryan B, Ahmad RN, Nguyen TTD, Umaña A, Monét Roberts L, Sobol P, et al. Fusobacterium nucleatum induces proliferation and migration in pancreatic cancer cells through host autocrine and paracrine signaling. Sci Signal. 2022;15(756): eabn4948. 36256708 PMC9732933 · DOI
  67. [71]Yang Y, Weng W, Peng J, Hong L, Yang L, Toiyama Y, et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-κB, and up-regulating expression of MicroRNA-21. Gastroenterology. 2017;152(4):851-66.e24. 27876571 PMC5555435 · DOI
  68. [72]Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013;14(2):195–206. 23954158 PMC3770529 · DOI · Paper page
  69. [73]Lamprinaki D, Garcia-Vello P, Marchetti R, Hellmich C, McCord KA, Bowles KM, et al. Siglec-7 mediates immunomodulation by colorectal cancer-associated Fusobacterium nucleatum ssp. animalis. Front Immunol. 2021;12:744184. 34659241 PMC8517482 · DOI
  70. [74]Parhi L, Alon-Maimon T, Sol A, Nejman D, Shhadeh A, Fainsod-Levi T, et al. Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression. Nat Commun. 2020;11(1):3259. 32591509 PMC7320135 · DOI · Paper page
  71. [75]Zhang N, Liu Y, Yang H, Liang M, Wang X, Wang M, et al. Clinical significance of Fusobacterium nucleatum infection and regulatory T cell enrichment in esophageal squamous cell carcinoma. Pathol Oncol Res. 2021;27:1609846. 34305476 PMC8300010 · DOI
  72. [76]Sun J, Tang Q, Yu S, Xie M, Zheng W, Chen G, et al. F. nucleatum facilitates oral squamous cell carcinoma progression via GLUT1-driven lactate production. EBioMedicine. 2023;88:104444. 36709580 PMC9900488 · DOI
  73. [78]Cao Y, Wang Z, Yan Y, Ji L, He J, Xuan B, et al. Enterotoxigenic Bacteroides fragilis promotes intestinal inflammation and malignancy by inhibiting exosome-packaged miR-149-3p. Gastroenterology. 2021;161(5):1552-66.e12. 34371001 · DOI
  74. [79]Park PH, Keith K, Calendo G, Jelinek J, Madzo J, Gharaibeh RZ, et al. Association between gut microbiota and CpG island methylator phenotype in colorectal cancer. Gut Microbes. 2024;16(1):2363012. 38860458 PMC11174071 · DOI
  75. [80]Li G, Xu W, Zhang L, Liu T, Jin G, Song J, et al. Development and validation of a CIMP-associated prognostic model for hepatocellular carcinoma. EBioMedicine. 2019;47:128–41. 31492561 PMC6796541 · DOI
  76. [81]Chang WL, Yeh YC, Sheu BS. The impacts of H. pylori virulence factors on the development of gastroduodenal diseases. J Biomed Sci. 2018;25(1):68. 30205817 PMC6131906 · DOI
  77. [82]Foegeding NJ, Caston RR, McClain MS, Ohi MD, Cover TL. An overview of Helicobacter pylori VacA toxin biology. Toxins. 2016;8(6):173. 27271669 PMC4926140 · DOI
  78. [83]Xu S, Wu X, Zhang X, Chen C, Chen H, She F. CagA orchestrates eEF1A1 and PKCδ to induce interleukin-6 expression in Helicobacter pylori -infected gastric epithelial cells. Gut Pathog. 2020;12:31. 32636937 PMC7333391 · DOI
  79. [84]Yong X, Tang B, Li BS, Xie R, Hu CJ, Luo G, et al. Helicobacter pylori virulence factor CagA promotes tumorigenesis of gastric cancer via multiple signaling pathways. Cell Commun Signal. 2015;13:30. 26160167 PMC4702319 · DOI
  80. [85]Teymournejad O, Mobarez AM, Hassan ZM, Abadi Talebi Bezmin A. Binding of the Helicobacter pylori OipA causes apoptosis of host cells via modulation of Bax/Bcl-2 levels. Sci Rep. 2017;7(1):8036. 28808292 PMC5556102 · DOI
  81. [86]Fan X, Alekseyenko AV, Wu J, Peters BA, Jacobs EJ, Gapstur SM, et al. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut. 2018;67(1):120–7. 27742762 PMC5607064 · DOI
  82. [87]Hajishengallis G, Wang M, Liang S, Triantafilou M, Triantafilou K. Pathogen induction of CXCR4/TLR2 cross-talk impairs host defense function. Proc Natl Acad Sci USA. 2008;105(36):13532–7. 18765807 PMC2533224 · DOI
  83. [88]Saba E, Farhat M, Daoud A, Khashan A, Forkush E, Menahem NH, et al. Oral bacteria accelerate pancreatic cancer development in mice. Gut. 2024;73(5):770–86. 38233197 · DOI
  84. [89]Tan Q, Ma X, Yang B, Liu Y, Xie Y, Wang X, et al. Periodontitis pathogen Porphyromonas gingivalis promotes pancreatic tumorigenesis via neutrophil elastase from tumor-associated neutrophils. Gut Microbes. 2022;14(1):2073785. 35549648 PMC9116393 · DOI
  85. [90]Wang X, Jia Y, Wen L, Mu W, Wu X, Liu T, et al. Porphyromonas gingivalis promotes colorectal carcinoma by activating the hematopoietic NLRP3 inflammasome. Cancer Res. 2021;81(10):2745–59. 34003774 · DOI
  86. [91]Yang X, Pan Y, Xu X, Tong T, Yu S, Zhao Y, et al. Sialidase deficiency in Porphyromonas gingivalis increases IL-12 secretion in stimulated macrophages through regulation of CR3, IncRNA GAS5 and miR-21. Front Cell Infect Microbiol. 2018;8:100. 29675399 PMC5895773 · DOI
  87. [92]Rocha FG, Moye ZD, Ottenberg G, Tang P, Campopiano DJ, Gibson FC 3rd, et al. Porphyromonas gingivalis sphingolipid synthesis limits the host inflammatory response. J Dent Res. 2020;99(5):568–76. 32105543 PMC7174802 · DOI
  88. [93]Liu S, Zhou X, Peng X, Li M, Ren B, Cheng G, et al. Porphyromonas gingivalis promotes immunoevasion of oral cancer by protecting cancer from macrophage attack. J Immunol. 2020;205(1):282–9. 32471882 · DOI
  89. [94]Wang Y, Wan X, Wu X, Zhang C, Liu J, Hou S. Eubacterium rectale contributes to colorectal cancer initiation via promoting colitis. Gut Pathog. 2021;13(1):2. 33436075 PMC7805161 · DOI
  90. [95]Xu Z, Lv Z, Chen F, Zhang Y, Xu Z, Huo J, et al. Dysbiosis of human tumor microbiome and aberrant residence of Actinomyces in tumor-associated fibroblasts in young-onset colorectal cancer. Front Immunol. 2022;13:1008975. 36119074 PMC9481283 · DOI
  91. [96]Peng R, Liu S, You W, Huang Y, Hu C, Gao Y, et al. Gastric microbiome alterations are associated with decreased CD8+ tissue-resident memory T cells in the tumor microenvironment of gastric cancer. Cancer Immunol Res. 2022. 10.1158/2326-6066.CIR-22-0107. 35881964 · DOI
  92. [97]Jin C, Lagoudas GK, Zhao C, Bullman S, Bhutkar A, Hu B, et al. Commensal microbiota promote lung cancer development via γδ T cells. Cell. 2019;176(5):998-1013.e16. 30712876 PMC6691977 · DOI · Paper page
  93. [98]Pushalkar S, Hundeyin M, Daley D, Zambirinis CP, Kurz E, Mishra A, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov. 2018;8(4):403–16. 29567829 PMC6225783 · DOI · Paper page
  94. [99]Cani PD, Depommier C, Derrien M, Everard A, de Vos WM. Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms. Nat Rev Gastroenterol Hepatol. 2022;19(10):625–37. 35641786 · DOI · Paper page
  95. [100]Fan L, Xu C, Ge Q, Lin Y, Wong CC, Qi Y, et al. A. muciniphila suppresses colorectal tumorigenesis by inducing TLR2/NLRP3-mediated M1-like TAMs. Cancer Immunol Res. 2021;9(10):1111–24. 34389559 · DOI
  96. [102]Jiang Y, Xu Y, Zheng C, Ye L, Jiang P, Malik S, et al. Acetyltransferase from Akkermansia muciniphila blunts colorectal tumourigenesis by reprogramming tumour microenvironment. Gut. 2023;72(7):1308–18. 36754607 · DOI
  97. [103]Zhang YG, Xia Y, Zhang J, Deb S, Garrett S, Sun J. Intestinal vitamin D receptor protects against extraintestinal breast cancer tumorigenesis. Gut Microbes. 2023;15(1):2202593. 37074210 PMC10120454 · DOI
  98. [106]Ma WJ, Li ZH, Wu ZR, Liu F, Wang JK, Shi YJ, et al. PI3K-CCL2-CCR2-MDSCs axis: a potential pathway for tumor Clostridia-promoted CD 8(+) T lymphocyte infiltration in bile tract cancers. Neoplasia. 2023;43:100920. 37515847 PMC10407443 · DOI
  99. [107]Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165(6):1332–45. 27259147 · DOI · Paper page
  100. [108]Chen D, Jin D, Huang S, Wu J, Xu M, Liu T, et al. Clostridium butyricum, a butyrate-producing probiotic, inhibits intestinal tumor development through modulating Wnt signaling and gut microbiota. Cancer Lett. 2020;469:456–67. 31734354 · DOI
  101. [109]Zhang X, Yu D, Wu D, Gao X, Shao F, Zhao M, et al. Tissue-resident Lachnospiraceae family bacteria protect against colorectal carcinogenesis by promoting tumor immune surveillance. Cell Host Microbe. 2023;31(3):418-32.e8. 36893736 · DOI
  102. [110]Flaherty BR, Barratt J, Lane M, Talundzic E, Bradbury RS. Sensitive universal detection of blood parasites by selective pathogen-DNA enrichment and deep amplicon sequencing. Microbiome. 2021;9(1):1. 33388088 PMC7778815 · DOI
  103. [111]Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991–8. 12407406 · DOI · Paper page
  104. [112]Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–905. 32402160 · DOI · Paper page
  105. [113]Gao Y, Bi D, Xie R, Li M, Guo J, Liu H, et al. Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer. Signal Transduct Target Ther. 2021;6(1):398. 34795206 PMC8602417 · DOI
  106. [114]Boesch M, Baty F, Albrich WC, Flatz L, Rodriguez R, Rothschild SI, et al. Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer. Oncoimmunology. 2021;10(1):1988403. 34912592 PMC8667931 · DOI
  107. [115]Zhang S, Yang Y, Weng W, Guo B, Cai G, Ma Y, et al. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer. J Exp Clin Cancer Res. 2019;38(1):14. 30630498 PMC6327560 · DOI
  108. [116]Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140(6):821–32. 20303873 · DOI · Paper page
  109. [118]Brungs D, Lochhead A, Iyer A, Illemann M, Colligan P, Hirst NG, et al. Expression of cancer stem cell markers is prognostic in metastatic gastroesophageal adenocarcinoma. Pathology. 2019;51(5):474–80. 31230819 · DOI
  110. [119]Liang M, Liu Y, Zhang Z, Yang H, Dai N, Zhang N, et al. Fusobacterium nucleatum induces MDSCs enrichment via activation the NLRP3 inflammosome in ESCC cells, leading to cisplatin resistance. Ann Med. 2022;54(1):989–1003. 35435776 PMC9891225 · DOI
  111. [120]Kovács T, Mikó E, Ujlaki G, Sári Z, Bai P. The microbiome as a component of the tumor microenvironment. Adv Exp Med Biol. 2020;1225:137–53. 32030653 · DOI
  112. [122]Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF. The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science. 2018;359(6382):1366–70. 29567708 · DOI · Paper page
  113. [123]Kovaleva OV, Podlesnaya P, Sorokin M, Mochalnikova V, Kataev V, Khlopko YA, et al. Macrophage phenotype in combination with tumor microbiome composition predicts RCC patients’ survival: a pilot study. Biomedicines. 2022;10(7):1516. 35884821 PMC9312790 · DOI
  114. [124]Qiao H, Tan XR, Li H, Li JY, Chen XZ, Li YQ, et al. Association of intratumoral microbiota with prognosis in patients with nasopharyngeal carcinoma from 2 hospitals in China. JAMA Oncol. 2022;8(9):1301–9. 35834269 PMC9284409 · DOI
  115. [126]Kovaleva O, Podlesnaya P, Rashidova M, Samoilova D, Petrenko A, Mochalnikova V, et al. Prognostic significance of the microbiome and stromal cells phenotype in esophagus squamous cell carcinoma. Biomedicines. 2021;9(7):743. 34203319 PMC8301468 · DOI
  116. [127]Battaglia TW, Mimpen IL, Traets JJH, van Hoeck A, Zeverijn LJ, Geurts BS, et al. A pan-cancer analysis of the microbiome in metastatic cancer. Cell. 2024;187(9):2324-35.e19. 38599211 · DOI
  117. [128]Sakamoto Y, Mima K, Ishimoto T, Ogata Y, Imai K, Miyamoto Y, et al. Relationship between Fusobacterium nucleatum and antitumor immunity in colorectal cancer liver metastasis. Cancer Sci. 2021;112(11):4470–7. 34464993 PMC8586672 · DOI
  118. [129]Xu C, Fan L, Lin Y, Shen W, Qi Y, Zhang Y, et al. Fusobacterium nucleatum promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization. Gut Microbes. 2021;13(1):1980347. 34632963 PMC8510564 · DOI
  119. [130]Hsueh CY, Huang Q, Gong H, Shen Y, Sun J, Lau HC, et al. A positive feed-forward loop between Fusobacterium nucleatum and ethanol metabolism reprogramming drives laryngeal cancer progression and metastasis. iScience. 2022;25(2):103829. 35198889 PMC8851092 · DOI
  120. [131]Casasanta MA, Yoo CC, Udayasuryan B, Sanders BE, Umaña A, Zhang Y, et al. Fusobacterium nucleatum host-cell binding and invasion induces IL-8 and CXCL1 secretion that drives colorectal cancer cell migration. Sci Signal. 2020;13(641): eaba9157. 32694172 PMC7454160 · DOI
  121. [132]Morrissey SM, Zhang F, Ding C, Montoya-Durango DE, Hu X, Yang C, et al. Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming. Cell Metab. 2021;33(10):2040-58.e10. 34559989 PMC8506837 · DOI
  122. [133]Domenis R, Cifù A, Marinò D, Fabris M, Niazi KR, Soon-Shiong P, et al. Toll-like receptor-4 activation boosts the immunosuppressive properties of tumor cells-derived exosomes. Sci Rep. 2019;9(1):8457. 31186484 PMC6560033 · DOI
  123. [134]Guo S, Chen J, Chen F, Zeng Q, Liu WL, Zhang G. Exosomes derived from Fusobacterium nucleatum —infected colorectal cancer cells facilitate tumour metastasis by selectively carrying miR-1246/92b-3p/27a-3p and CXCL16. Gut. 2020. 10.1136/gutjnl-2020-321187. 33172926 · DOI
  124. [135]Le MT, Hamar P, Guo C, Basar E, Perdigão-Henriques R, Balaj L, et al. miR-200-containing extracellular vesicles promote breast cancer cell metastasis. J Clin Invest. 2014;124(12):5109–28. 25401471 PMC4348969 · DOI
  125. [136]Salimu J, Webber J, Gurney M, Al-Taei S, Clayton A, Tabi Z. Dominant immunosuppression of dendritic cell function by prostate-cancer-derived exosomes. J Extracell Vesicles. 2017;6(1):1368823. 28959385 PMC5613918 · DOI
  126. [137]Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol. 2015;17(6):816–26. 25985394 PMC5769922 · DOI · Paper page
  127. [138]Pan Z, Zhao R, Li B, Qi Y, Qiu W, Guo Q, et al. EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3. Mol Cancer. 2022;21(1):16. 35031058 PMC8759291 · DOI
  128. [139]Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527(7578):329–35. 26524530 PMC4788391 · DOI · Paper page
  129. [140]Webber J, Steadman R, Mason MD, Tabi Z, Clayton A. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res. 2010;70(23):9621–30. 21098712 · DOI
  130. [141]Fong MY, Zhou W, Liu L, Alontaga AY, Chandra M, Ashby J, et al. Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat Cell Biol. 2015;17(2):183–94. 25621950 PMC4380143 · DOI · Paper page
  131. [142]Kucharzewska P, Christianson HC, Welch JE, Svensson KJ, Fredlund E, Ringnér M, et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci USA. 2013;110(18):7312–7. 23589885 PMC3645587 · DOI · Paper page
  132. [143]Liu Y, Cao X. Characteristics and significance of the pre-metastatic niche. Cancer Cell. 2016;30(5):668–81. 27846389 · DOI
  133. [144]Serna G, Ruiz-Pace F, Hernando J, Alonso L, Fasani R, Landolfi S, et al. Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer. Ann Oncol. 2020;31(10):1366–75. 32569727 PMC7542577 · DOI
  134. [145]Salvucci M, Crawford N, Stott K, Bullman S, Longley DB, Prehn JHM. Patients with mesenchymal tumours and high Fusobacteriales prevalence have worse prognosis in colorectal cancer (CRC). Gut. 2022;71(8):1600–12. 34497144 PMC9279747
  135. [146]Hamada T, Zhang X, Mima K, Bullman S, Sukawa Y, Nowak JA, et al. Fusobacterium nucleatum in colorectal cancer relates to immune response differentially by tumor microsatellite instability status. Cancer Immunol Res. 2018;6(11):1327–36. 30228205 PMC6215508 · DOI
  136. [147]Kim HE, Kim J, Maeng S, Oh B, Hwang KT, Kim BS. Microbiota of breast tissue and its potential association with regional recurrence of breast cancer in Korean women. J Microbiol Biotechnol. 2021;31(12):1643–55. 34584037 PMC9705848 · DOI
  137. [148]Neuzillet C, Marchais M, Vacher S, Hilmi M, Schnitzler A, Meseure D, et al. Prognostic value of intratumoral Fusobacterium nucleatum and association with immune-related gene expression in oral squamous cell carcinoma patients. Sci Rep. 2021;11(1):7870. 33846399 PMC8041800 · DOI
  138. [149]Bullman S, Pedamallu CS, Sicinska E, Clancy TE, Zhang X, Cai D, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017;358(6369):1443–8. 29170280 PMC5823247 · DOI · Paper page
  139. [150]Zhang X, Chen X, Guo Y, Gao G, Wang D, Wu Y, et al. Dual Gate-controlled therapeutics for overcoming bacterium-induced drug resistance and potentiating cancer immunotherapy. Angew Chem Int Ed Engl. 2021;60(25):14013–21. 33768682 · DOI
  140. [151]Derosa L, Routy B, Desilets A, Daillère R, Terrisse S, Kroemer G, et al. Microbiota-centered interventions: the next breakthrough in immuno-oncology? Cancer Discov. 2021;11(10):2396–412. 34400407 · DOI · Paper page
  141. [152]Wang M, Rousseau B, Qiu K, Huang G, Zhang Y, Su H, et al. Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses. Nat Biotechnol. 2024;42(8):1263–74. 37749267 PMC12892252 · DOI
  142. [153]Roemhild R, Bollenbach T, Andersson DI. The physiology and genetics of bacterial responses to antibiotic combinations. Nat Rev Microbiol. 2022;20(8):478–90. 35241807 · DOI
  143. [154]Sommer MOA, Dantas G, Church GM. Functional characterization of the antibiotic resistance reservoir in the human microflora. Science. 2009;325(5944):1128–31. 19713526 PMC4720503 · DOI · Paper page
  144. [155]Sepich-Poore GD, Zitvogel L, Straussman R, Hasty J, Wargo JA, Knight R. The microbiome and human cancer. Science. 2021;371(6536): eabc4552. 33766858 PMC8767999 · DOI · Paper page
  145. [156]van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407–15. 23323867 · DOI · Paper page
  146. [157]Mullish BH, Merrick B, Quraishi MN, Bak A, Green CA, Moore DJ, et al. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. J Hosp Infect. 2024;148:189–219. 38609760 · DOI
  147. [161]Wu X, Zhang T, Chen X, Ji G, Zhang F. Microbiota transplantation: targeting cancer treatment. Cancer Lett. 2019;452:144–51. 30905818 · DOI
  148. [163]Soto-Pantoja DR, Gaber M, Arnone AA, Bronson SM, Cruz-Diaz N, Wilson AS, et al. Diet alters entero-mammary signaling to regulate the breast microbiome and tumorigenesis. Cancer Res. 2021;81(14):3890–904. 34083249 PMC8981494 · DOI
  149. [164]Cullin N, Azevedo Antunes C, Straussman R, Stein-Thoeringer CK, Elinav E. Microbiome and cancer. Cancer Cell. 2021;39(10):1317–41. 34506740 · DOI · Paper page
  150. [165]Han ZY, Fu ZJ, Wang YZ, Zhang C, Chen QW, An JX, et al. Probiotics functionalized with a gallium-polyphenol network modulate the intratumor microbiota and promote anti-tumor immune responses in pancreatic cancer. Nat Commun. 2024;15(1):7096. 39154092 PMC11330462 · DOI
  151. [166]Choudhury A, Ortiz PS, Young M, Mahmud MT, Stoffel RT, Greathouse KL, et al. Control of Helicobacter pylori with engineered probiotics secreting selective guided antimicrobial peptides. Microbiol Spectr. 2023;11(5): e0201423. 37712669 PMC10580918 · DOI
  152. [167]Chen L, Zhao R, Shen J, Liu N, Zheng Z, Miao Y, et al. Antibacterial Fusobacterium nucleatum -mimicking nanomedicine to selectively eliminate tumor-colonized bacteria and enhance immunotherapy against colorectal cancer. Adv Mater. 2023;35(45):2306281. 37722134 · DOI
  153. [168]Zheng DW, Deng WW, Song WF, Wu CC, Liu J, Hong S, et al. Biomaterial-mediated modulation of oral microbiota synergizes with PD-1 blockade in mice with oral squamous cell carcinoma. Nat Biomed Eng. 2022;6(1):32–43. 34750535 · DOI
  154. [170]Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 2014;13(9):655–72. 25103255 PMC4455970 · DOI · Paper page
  155. [171]Porcari S, Fusco W, Spivak I, Fiorani M, Gasbarrini A, Elinav E, et al. Fine-tuning the gut ecosystem: the current landscape and outlook of artificial microbiome therapeutics. Lancet Gastroenterol Hepatol. 2024;9(5):460–75. 38604200 · DOI
  156. [172]LaCourse KD, Zepeda-Rivera M, Kempchinsky AG, Baryiames A, Minot SS, Johnston CD, et al. The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota. Cell Rep. 2022;41(7):111625. 36384132 PMC10790632 · DOI
  157. [173]Qu X, Yin F, Pei M, Chen Q, Zhang Y, Lu S, et al. Modulation of intratumoral Fusobacterium nucleatum to enhance sonodynamic therapy for colorectal cancer with reduced phototoxic skin injury. ACS Nano. 2023;17(12):11466–80. 37201179 PMC10311605 · DOI
  158. [174]Wang X, Chen Q, Zhu Y, Wang K, Chang Y, Wu X, et al. Destroying pathogen-tumor symbionts synergizing with catalytic therapy of colorectal cancer by biomimetic protein-supported single-atom nanozyme. Signal Transduct Target Ther. 2023;8(1):277. 37474504 PMC10359331 · DOI
  159. [177]Salter SJ, Cox MJ, Turek EM, Calus ST, Cookson WO, Moffatt MF, et al. Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. BMC Biol. 2014;12:87. 25387460 PMC4228153 · DOI · Paper page
  160. [178]Knights D, Kuczynski J, Charlson ES, Zaneveld J, Mozer MC, Collman RG, et al. Bayesian community-wide culture-independent microbial source tracking. Nat Methods. 2011;8(9):761–3. 21765408 PMC3791591 · DOI
  161. [179]Davis NM, Proctor DM, Holmes SP, Relman DA, Callahan BJ. Simple statistical identification and removal of contaminant sequences in marker-gene and metagenomics data. Microbiome. 2018;6(1):226. 30558668 PMC6298009 · DOI · Paper page
  162. [181]Fessler J, Matson V, Gajewski TF. Exploring the emerging role of the microbiome in cancer immunotherapy. J Immunother Cancer. 2019;7(1):108. 30995949 PMC6471869 · DOI
  163. [182]Chen H, Zhu Y, Zhang C, Hu L, Yang K. Engineered bacteria in tumor immunotherapy. Cancer Lett. 2024;589:216817. 38492769 · DOI
  164. [183]Liu CH, Liu H, Ge B. Innate immunity in tuberculosis: host defense vs pathogen evasion. Cell Mol Immunol. 2017;14(12):963–75. 28890547 PMC5719146 · DOI
  165. [184]Lukic A, Larssen P, Fauland A, Samuelsson B, Wheelock CE, Gabrielsson S, et al. GM-CSF- and M-CSF-primed macrophages present similar resolving but distinct inflammatory lipid mediator signatures. FASEB J. 2017;31(10):4370–81. 28637652 · DOI
  166. [185]Wei B, Pan J, Yuan R, Shao B, Wang Y, Guo X, et al. Polarization of tumor-associated macrophages by nanoparticle-loaded escherichia coli combined with immunogenic cell death for cancer immunotherapy. Nano Lett. 2021;21(10):4231–40. 33998789 · DOI
  167. [186]Lin Q, Rong L, Jia X, Li R, Yu B, Hu J, et al. IFN-γ-dependent NK cell activation is essential to metastasis suppression by engineered Salmonella. Nat Commun. 2021;12(1):2537. 33953170 PMC8099885 · DOI
  168. [187]Wang W, Qian C, Wang T, Jiang Y, Zhou Y, Liu K, et al. A combination of faecal and intratumour microbial community profiling reveals novel diagnostic and prognostic biomarkers for pancreatic tumours. Clin Transl Med. 2024;14(6): e1726. 38822473 PMC11142927 · DOI
  169. [188]Bello S, Vengoechea JJ, Ponce-Alonso M, Figueredo AL, Mincholé E, Rezusta A, et al. Core microbiota in central lung cancer with streptococcal enrichment as a possible diagnostic marker. Arch Bronconeumol. 2021;57(11):681–9. 35699005 · DOI
  170. [190]Aykut B, Pushalkar S, Chen R, Li Q, Abengozar R, Kim JI, et al. The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. Nature. 2019;574(7777):264–7. 31578522 PMC6858566 · DOI · Paper page
  171. [191]Alam A, Levanduski E, Denz P, Villavicencio HS, Bhatta M, Alhorebi L, et al. Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer. Cancer Cell. 2022;40(2):153-67.e11. 35120601 PMC8847236 · DOI
  172. [192]Liu NN, Yi CX, Wei LQ, Zhou JA, Jiang T, Hu CC, et al. The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells. Cancer Cell. 2023;41(11):1927-44.e9. 37738973 · DOI
  173. [193]Zhong M, Xiong Y, Zhao J, Gao Z, Ma J, Wu Z, et al. Candida albicans disorder is associated with gastric carcinogenesis. Theranostics. 2021;11(10):4945–56. 33754037 PMC7978306 · DOI
  174. [194]Dohlman AB, Klug J, Mesko M, Gao IH, Lipkin SM, Shen X, et al. A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors. Cell. 2022;185(20):3807-22.e12. 36179671 PMC9564002 · DOI

Cited by

Sorted by citations

Authors
Wang, N., Wu, S., Huang, L., Hu, Y., He, X., He, J., Hu, B., Xu, Y., Rong, Y., Yuan, C., Zeng, X., & Wang, F.
Affiliations
  • Zhongnan Hospital of Wuhan University (CN)
  • Wuhan Children's Hospital (CN)
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Corresponding author
  • Yuan, Chunhui
  • Wang, Fubing
ORCID
Venue
Journal of Biomedical Science
Publisher
Springer Science and Business Media LLC
Published
2025-02-19
Volume
32
Issue
1
Pages
23-23
ISSN
  • 1021-7770 (ISSN-L)
  • 1423-0127
DOI
10.1186/s12929-025-01117-x
PMC
PMC11837407
OpenAlex
W4407685244
Cited by
62
References
20
Citations by year
2026: 31 · 2025: 31
FWCI
5.49
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Biomedical Science (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Natural Science Foundation of China (No.12175167)
  • Science Fund for Creative Research Groups of the Natural Science Foundation of Hubei Province (No. 2022CFA005)
  • Basic and Clinical Medical Research Joint Fund of Zhongnan Hospital, Wuhan University (No. ZNLH202209)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Cancer Research and Treatments
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
intratumoral microbiota, tumor microbiome, tumor immune microenvironment, immunomodulation, host-pathogen interaction, tumor growth, cancer immunotherapy, cancer prognosis, cancer therapy
MeSH terms
Humans, Immunotherapy, Neoplasms, Tumor Microenvironment, Microbiota

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review